Merck and Pfizer Pull PR Coup With Corning Glass Partnership
This time, when Donald Trump hosted an event with two Big Pharma CEOs, the topic wasn’t drug pricing: it was jobs in American manufacturing, tied to a new, stronger glass vial. But it also looks like an early case study in effective engagement with an unpredictable White House.
You may also be interested in...
The US president made what seemed to be a retaliatory statement about high drug prices after Merck CEO Ken Frazier resigned from his jobs council.
Why not wait for the confirmatory trial to read out before approval, at least in the context of an especially uncertain or controversial surrogate marker?
The US Medicare Payment Advisory Commission is continuing its work on proposals to overhaul federal payment for physician administered drugs. That is an ominous message for the biopharma industry as it reels from passage of dramatic pricing legislation earlier this year.